Alembic Ltd

Alembic Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Alembic Ltd

₹ 87.9 0.33%
26 May - close price
alembiclimited.com BSE: 506235 NSE: ALEMBICLTD
About

Alembic Limited is engaged in the businesses of Pharmaceuticals, Real Estate, and Power Assets. The company was started in 1907 as the flagship company of the Alembic Group. In 2010, the company demerged its core pharmaceutical business (formulations) into a wholly-owned subsidiary, Alembic Pharma Ltd and after the demerger, APL became the flagship company of the Alembic Group.
With its registered office in Vadodra, Alembic Ltd currently holds a 28.41% stake in Alembic Pharma Ltd and a 19.01% stake in another group entity Paushak Limited.[1]

Key Points

Business Segments
A) Real Estate (~80% in FY24 vs 59% in FY22): [1] [2] The company is involved in the construction of residential & commercial real estate projects. It also leases commercial properties. [3] Real Estate business experienced strong growth between FY23-FY24 bolstered by strong demand and higher property prices. [4]

Website BSE NSE
  • Market Cap ₹ 2,255 Cr.
  • Current Price ₹ 87.9
  • High / Low ₹ 126 / 70.5
  • Stock P/E 7.10
  • Book Value ₹ 95.2
  • Dividend Yield 2.73 %
  • ROCE 6.28 %
  • ROE 13.3 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Stock is trading at 0.92 times its book value
  • Market value of investments Rs.5,490 Cr. is more than the Market Cap Rs.2,255 Cr.
  • Company has been maintaining a healthy dividend payout of 20.7%

Cons

  • Company has a low return on equity of 13.2% over last 3 years.
  • Earnings include an other income of Rs.73.0 Cr.
  • Working capital days have increased from 91.8 days to 141 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Consumer Discretionary Realty Realty Residential, Commercial Projects

Part of BSE Consumer Discretionary BSE 1000

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
37 37 32 39 49 51 53 58 60 50 56 74 60
24 26 22 28 25 30 33 32 33 30 33 47 40
Operating Profit 13 11 10 12 24 20 20 26 27 20 23 27 20
OPM % 36% 30% 31% 30% 49% 40% 37% 46% 45% 39% 42% 37% 34%
-9 3 48 2 2 2 66 4 3 4 65 2 2
Interest 0 0 0 0 0 0 1 1 1 1 1 1 1
Depreciation 2 2 2 3 1 2 3 3 3 3 3 3 3
Profit before tax 3 12 56 11 24 19 82 27 27 20 85 26 18
Tax % -55% 14% 8% 9% 12% 10% 6% 5% 12% 10% 10% 13% 48%
48 44 91 61 72 56 121 65 68 62 128 60 67
EPS in Rs 1.88 1.73 3.53 2.39 2.81 2.17 4.71 2.55 2.67 2.40 5.00 2.34 2.61
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
144 134 147 125 124 74 74 78 127 157 222 240
134 128 140 114 106 71 62 64 87 101 128 150
Operating Profit 10 6 7 11 18 3 11 14 40 57 94 90
OPM % 7% 5% 5% 9% 15% 4% 15% 18% 32% 36% 42% 38%
21 25 25 37 29 93 10 89 54 55 75 73
Interest 1 0 0 0 0 0 0 0 0 1 2 2
Depreciation 6 6 5 4 3 3 4 5 7 8 11 12
Profit before tax 23 25 27 44 45 93 17 98 87 103 156 149
Tax % -3% 2% -3% 5% 8% 0% 19% 12% 7% 10% 7% 15%
107 235 145 163 213 329 343 222 191 269 311 317
EPS in Rs 3.99 8.78 5.45 6.10 8.30 12.82 13.35 8.65 7.42 10.46 12.10 12.36
Dividend Payout % 4% 2% 4% 3% 2% 5% 2% 21% 30% 23% 20% 19%
Compounded Sales Growth
10 Years: 6%
5 Years: 27%
3 Years: 24%
TTM: 8%
Compounded Profit Growth
10 Years: 3%
5 Years: -1%
3 Years: 17%
TTM: 3%
Stock Price CAGR
10 Years: 12%
5 Years: -8%
3 Years: 10%
1 Year: -21%
Return on Equity
10 Years: 14%
5 Years: 11%
3 Years: 13%
Last Year: 13%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 53 53 53 53 51 51 51 51 51 51 51 51
Reserves 474 750 858 1,032 1,157 1,367 2,246 2,445 2,027 2,134 2,287 2,394
0 9 0 0 0 0 0 0 0 9 14 11
91 64 81 73 57 53 112 135 127 134 150 134
Total Liabilities 619 875 992 1,159 1,266 1,471 2,409 2,632 2,205 2,329 2,503 2,590
169 146 171 179 209 225 265 297 321 369 409 472
CWIP 2 0 0 0 0 3 6 0 0 1 0 2
Investments 299 605 732 913 1,001 1,133 2,047 2,208 1,754 1,786 1,900 1,974
149 124 89 67 55 110 91 127 130 173 194 142
Total Assets 619 875 992 1,159 1,266 1,471 2,409 2,632 2,205 2,329 2,503 2,590

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
22 10 52 24 22 7 -2 -18 39 23 86 120
5 -5 -47 -22 68 57 -35 19 7 26 -27 -54
-25 -5 -5 -3 -89 -6 -15 -6 -46 -48 -58 -68
Net Cash Flow 2 -0 -0 -1 1 57 -52 -5 -0 0 1 -1
Free Cash Flow 22 11 38 14 -1 -15 -49 -51 14 -33 36 43
CFO/OP 222% 172% 771% 245% 145% 246% 0% -63% 112% 39% 109% 154%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 122 76 54 74 40 44 69 71 67 46 49 49
Inventory Days 880 659 438 247 289 411 2,112 2,885 3,694 249
Days Payable 200 144 128 125 202 151 693 640 1,237 114
Cash Conversion Cycle 801 591 364 195 126 305 1,488 2,316 67 2,502 49 184
Working Capital Days 235 172 39 20 13 22 97 223 118 77 57 141
ROCE % 4% 4% 4% 4% 7% 1% 4% 4% 5% 7% 6%

Insights

In beta
Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Investment Stake in Alembic Pharmaceuticals Ltd (APL)
%

Log in to view insights

Please log in to see hidden values.

Login
Number of Equity Shares held in Paushak Ltd
Number
API Production Capacity (Erythromycin Estolate)
MT/Month ・Standalone data
Power Generation - Co-generation Plant
Lakh Units ・Standalone data
Power Generation - Windmills
Lakh Units ・Standalone data
API Production Volume (Erythromycin Estolate - Peak Month)
MT ・Standalone data
Commercial Leasable Area (New Office Building) Pre-leased
% ・Standalone data
Power Generation - Co-generation Plant and Windmills
Lakh Units ・Standalone data
Project Sales Progress - The Garden
% ・Standalone data
Project Sales Progress - The Villa
% ・Standalone data
Project Sales Progress - Townhouse 24
% ・Standalone data
Renewable Power Consumption (API Operations)
GJ ・Standalone data
R&D Expenditure (Percentage of Turnover)
% ・Standalone data

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
70.88% 70.88% 70.88% 70.88% 70.88% 70.88% 70.88% 70.88% 70.88% 70.88% 70.88% 70.88%
0.72% 0.85% 0.89% 1.07% 1.42% 1.97% 1.78% 1.65% 1.50% 1.38% 1.29% 1.25%
3.93% 3.40% 0.04% 0.04% 0.04% 0.08% 0.06% 0.05% 0.05% 0.05% 0.05% 0.05%
24.46% 24.87% 28.17% 28.02% 27.66% 27.07% 27.27% 27.41% 27.57% 27.68% 27.78% 27.81%
No. of Shareholders 81,73282,94794,01299,13098,4781,02,2491,07,4231,06,7321,07,5101,06,4701,04,1031,02,008

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings